Internal Medicine, Gastroenterology · Newport, OR
NPI
1740280429
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
407 N Coast Hwy Ste 200
Newport, OR, 97365
Phone (541) 265-8309
Groups this clinician bills Medicare through
Medicare paid, 2024
$123K
1,235 services
Medicare patients, 2024
592
Average age 72
Drug cost, 2024
$664K
4,861 prescriptions
Company payments, 2025
$317
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nazmul Hoque was code 99214 (office e&m - established), 303 times for 179 patients. In total Nazmul Hoque billed 1,235 services in 42 codes, and Medicare paid $123K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 303 | 179 | $93.24 | $28K |
| 99213 Office E&M - Established | Office | 216 | 174 | $60.72 | $13K |
| 43239 Upper GI Endoscopy | Facility | 154 | 145 | $82.61 | $13K |
| 45380 Lower GI Endoscopy - Other | Facility | 140 | 140 | $121.29 | $17K |
| 45385 Colonoscopy - Lesion Removal | Facility | 114 | 114 | $210.96 | $24K |
| 99203 Office E&M - New | Office | 93 | 93 | $69.77 | $6,489 |
| 99204 Office E&M - New | Office | 38 | 38 | $129.10 | $4,906 |
| 85610 Clinical Chemistry | Office | 25 | 22 | $4.20 | $105 |
| 43235 Upper GI Endoscopy | Facility | 22 | 21 | $90.94 | $2,001 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 22 | 22 | $186.11 | $4,094 |
| 99202 Office E&M - New | Office | 12 | 12 | $31.72 | $381 |
By year: 2022 $115K for 1,467 services; 2023 $124K for 1,230 services; 2024 $123K for 1,235 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 25 | 22 | $4.20 | $105 |
Medicare prescription drug claims, 2024
In 2024, the drug Nazmul Hoque prescribed most often to Medicare patients was Omeprazole, with 452 prescriptions and refills. In total Nazmul Hoque wrote 4,861 Medicare prescriptions that cost $664K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Omeprazole Generic | 452 | 1,019 | 151 | $7,814 |
| Pantoprazole Sodium Generic | 172 | 392 | 51 | $2,529 |
| Atorvastatin Calcium Generic | 158 | 324 | 33 | $1,939 |
| Lisinopril Generic | 156 | 345 | 35 | $1,101 |
| Levothyroxine Sodium Generic | 145 | 342 | 29 | $2,001 |
| Metformin Hcl Generic | 115 | 247 | 27 | $697 |
| Furosemide Generic | 102 | 161 | 22 | $542 |
| Tramadol Hcl Generic | 101 | 101 | 14 | $842 |
| Carvedilol Generic | 95 | 165 | 17 | $1,843 |
| Linzess Linaclotide | 91 | 126 | 21 | $69K |
| Gabapentin Generic | 87 | 130 | 13 | $1,785 |
| Potassium Chloride Generic | 81 | 123 | 13 | $1,198 |
| Donepezil Hcl Generic | 76 | 142 | 13 | $798 |
| Budesonide Dr Budesonide | 74 | 95 | 17 | $16K |
| Amlodipine Besylate Generic | 73 | 207 | 18 | $587 |
Brand drugs: 644 claims; generic drugs: 4,198 claims; opioid claims: 244.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nazmul Hoque $317 ($317 in general payments such as food, travel and fees) from 9 companies. The largest payer was Genzyme Corporation with $78.03.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 3 | $78.03 |
| Novo Nordisk Inc NVO | 2 | $48.39 |
| Pfizer Inc. PFE | 2 | $39.94 |
| Lilly USA, LLC LLY | 2 | $35.62 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $34.33 |
| Exact Sciences Corporation EXAS | 1 | $23.01 |
| GlaxoSmithKline, LLC. GSK | 1 | $20.62 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $19.46 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 1 | $17.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.